TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06154278: Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

Sponsor: University of Maryland, Baltimore · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$352,800

Rescue Site Savings

+$235,200

Unlock Full NCT06154278 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06154278 Rescue Dossier →